Bluejay Diagnostics Details SYMON-II Clinical Dataset
Bluejay Diagnostics announced details of its SYMON-II clinical validation dataset, a step toward regulatory submission for its Symphony™ IL-6 Test.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Bluejay Diagnostics releases IL-6 sepsis mortality risk data from SYMON-II study
Bluejay Diagnostics released baseline data from its SYMON-II clinical validation study evaluating IL-6 for 28-day mortality risk in sepsis. Non-survivors showed greater illness severity at baseline. The Symphony IL-6 test remains in development and is not cleared for commercial clinical use in the US.